Autologous Cell Therapy Market - By Therapy (Autologous Cellular Immunotherapies, Autologous Stem Cell Therapy), By Source (Bone Marrow, Epidermis), By Application (Cancer, Orthopedics), By End-use (Hospitals & Clinics, Research Centers) & Forecast 2023 - 2032

Autologous Cell Therapy Market Size

Autologous Cell Therapy Market size valued at USD 12.9 billion in 2022 and is estimated to grow at 11.6% CAGR from 2023 to 2032. Rising prevalence of chronic disease coupled with growing demand for personalized treatment is expected to boost the market growth. For instance, in 2018, Food and Drug Administration (FDA) approved the CAR T-cell therapy tisagenlecleucel (Kymriah) for adults with certain types of non-Hodgkin lymphoma, a second CAR T-cell therapy approved for lymphoma. Thus, growing demand and adoption of personalized autologous cell therapies such as CAR-T is set to boost the market size.
 

Autologous cell therapy is a novel therapeutic approach that uses an individual’s cells, that are cultured and expanded outside the patient’s body and reintroduced into the donor. It involves the collection, isolation, and manipulation of cells from the patient's body, typically from sources such as blood, bone marrow, or adipose tissue. This personalized treatment approach offers several advantages, including a reduced risk of immune rejection or adverse reactions, as the cells used are a genetic match to the patient.
 

COVID-19 Impact

The global spread of COVID-19 infection did not have material effect on autologous cell therapy market. Various research institutes and government organizations across the regions were focusing on rapid and effective technologies for the treatment of life-threatening diseases including COVID-19 outbreak. For instance, according to the ClinicalTrial.gov report, mesenchymal stem cells were investigated to determine the efficacy, effective and safe approach for the treatment of COVID-19 infection. Also, several clinical trials were begun with respective to regenerative medicine.
 

Autologous Cell Therapy Market Trends

Increasing prevalence of chronic diseases such as blood cancer, autoimmune disorders, orthopedic conditions among others is slated to boost the market revenue. For instance, according to a recent study published by University of Oxford, autoimmune diseases affect around 10% of the global population and in UK around 1 in 10 individuals are affected with autoimmune disorder.
 

Thus, growing prevalence of serve chronic disease is propelling the demand for autologous cell therapy. Furthermore, autologous cell therapy promote tissue regeneration, enhance immune responses and provide personalized treatments along with regenerative and immunomodulatory properties lead to improved treatment outcomes, reduced risk of rejection or adverse reactions, and potentially lower long-term healthcare costs.
 

Autologous Cell Therapy Market Restraint

Systemic immunological reactions may significantly hinder the industry growth. Various adverse effects are associated with autologous cell therapy such as systemic inflammatory response syndrome (SIRS) and infection-induced systemic immune response, commonly known as sepsis, may lead to multiple organ dysfunction syndrome (MODS) and ultimately death. Furthermore, patients undergoing autologous stem cell transplantation possess risk of relapse and myelodysplasia. Also, few of the long-term effects caused due to autologous stem cell transplant include cataracts, infertility and chances of developing a secondary cancer.
 

Autologous Cell Therapy Market Analysis

The autologous cellular immunotherapies segment held over 50.9% of the autologous cell therapy market share in 2022. Autologous cellular immunotherapies involve collecting immune cells from the patient and modifying them to enhance their ability to recognize and attack specific target diseases. Also, autologous cellular immunotherapies, such as CAR-T cell therapy aims to boost the patient’s immune system ability to fight diseases, especially cancer more effectively.
 

The autologous cell therapy market from bone marrow segment is poised to reach USD 16.5 billion by 032. Autologous cellular immunotherapies, specifically those sourced from bone marrow contains high proportion of immune cells, including T cells, which can be easily accessed and isolated for therapeutic purposes. Also, bone marrow-derived cells possess high regenerative potential and have the ability to differentiate into multiple cell lineages, including bone, cartilage, muscle, and fat cells making them suitable for treating a wide range of conditions. Therefore, cells sourced from bone marrow for autologous cell therapy reduces the risk of immune rejection or adverse reactions, thereby fueling the industry demand.
 

The autologous cell therapy market size from cancer segment will observe around 12.4% CAGR during the forecast period. Autologous cell therapy have offered significant advantages in the treatment of various types of cancers, including hematological malignancies and solid tumors. They have potential to induce durable responses and improve long-term survival rates and can be tailored to target specific cancer markers or antigens allowing for precision and specificity in treatment. This targeted approach helps minimize damage to healthy tissues and reduces the risk of severe side effects often associated with conventional treatments such as chemotherapy or radiation therapy.
 

The autologous cell therapy market from hospitals & clinics segment dominated over USD 6 billion revenue in 2022. Availability of skilled medical professionals and advanced healthcare infrastructure has propelled the hospitals & clinics segment growth. Autologous cell therapy often involves intricate processes such as cell collection, isolation and reinfusion that require advanced medical technologies and expertise. Furthermore, favorable reimbursement policies, growing technological advancements in autologous cell therapy have increased the hospital admissions for treatments, thereby stimulating the market growth.
 

North America autologous cell therapy market accounted for 42.2% revenue share in 2022. The increasing prevalence of chronic disease and rising adoption of advanced medical technologies is expected to boost the market value. Furthermore, presence of well-established healthcare infrastructure, key companies and academic institutions contribute to the growth of autologous cell therapy. Moreover, growing demand for precision medicine, favorable government regulations and reimbursement policies further support the market expansion.
 

Autologous Cell Therapy Market Share

Major companies operating in the autologous cell therapy market include

• Lonza Group AG
• Novartis AG
• Bristol-Myers Squibb Company
• Corning Incorporated

These companies majorly adopt various strategies including collaborations, acquisitions, mergers, and partnerships to create a global footprint and sustain market competition.
 

Autologous Cell Therapy Industry News:

• In March 2022, Novartis signs initial agreement with Carisma Therapeutics for the manufacturing of HER 2 targeted CAR-M cell therapy. This strategy helped the company to bring their CAR-M cell therapy to patients by offering its proven state-of-the art cell and gene production capabilities, thereby drive revenue growth.
   
• In May 2020, Lonza and Noga Therapeutics collaborated to Develop Autologous Lentiviral Gene Therapy on the Cocoon Platform. This collaboration helped the company to bring novel autologous gene therapy for Primary Immune Deficiencies (PIDs) to the clinic and patients. This strategy helped the company to strengthen business relations and increase customer base.
   

The autologous cell therapy market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments:

Click here to Buy Section of this Report

Market, By Therapy

• Autologous Cellular Immunotherapies
• Autologous Stem Cell Therapy

Market, By Source

• Bone Marrow
• Epidermis
• Mesenchymal Stem Cells
• Other sources

Market, By Application

• Cancer
• Cardiovascular Disorders
• Neurodegenerative Disorders
• Orthopedics
• Other applications

Market, By End-use

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Research Centers
• Other end-users

The above information has been provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA